Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics

Ana Caroline C. Sá, Amy Webb, Yan Gong, Caitrin W. McDonough, Somnath Datta, Taimour Y. Langaee, Stephen T Turner, Amber L. Beitelshees, Arlene B. Chapman, Eric Boerwinkle, John G. Gums, Steven E. Scherer, Rhonda M. Cooper-Dehoff, Wolfgang Sadee, Julie A. Johnson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thiazide diuretics (TD) are commonly prescribed anti-hypertensives worldwide. However, <40% of patients treated with thiazide monotherapy achieve BP control. This study uses whole transcriptome sequencing to identify novel molecular markers associated with BP response to TD. We assessed global RNA expression levels in whole blood samples from 150 participants, representing patients in the upper and lower quartile of BP response to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) (50 whites) and from PEAR-2 (50 whites and 50 blacks). In each study cohort, we performed poly-A RNA-sequencing in baseline samples from 25 responders and 25 non-responders to hydrochlorothiazide (HCTZ) or chlorthalidone. At FDR adjusted p-value < 0.05, 29 genes were differentially expressed in relation to HCTZ or chlorthalidone BP response in whites. For each differentially expressed gene, replication was attempted in the alternate white group and PEAR-2 blacks. CEBPD (meta-analysis p = 1.8 × 10-11) and TSC22D3 (p = 1.9 × 10-9) were differentially expressed in all 3 cohorts, and explain, in aggregate, 21.9% of response variability to TD. This is the first report of the use of transcriptome-wide sequencing data to identify molecular markers of antihypertensive drug response. These findings support CEBPD and TSC22D3 as potential biomarkers of BP response to TD.

Original languageEnglish (US)
Article number16068
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Sodium Chloride Symporter Inhibitors
Gene Expression Profiling
Antihypertensive Agents
Blood Pressure
Pharmacogenetics
Chlorthalidone
Hydrochlorothiazide
Transcriptome
RNA Sequence Analysis
Thiazides
Genes
Meta-Analysis
Cohort Studies
Biomarkers
RNA
Messenger RNA

ASJC Scopus subject areas

  • General

Cite this

Sá, A. C. C., Webb, A., Gong, Y., McDonough, C. W., Datta, S., Langaee, T. Y., ... Johnson, J. A. (2017). Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Scientific Reports, 7(1), [16068]. https://doi.org/10.1038/s41598-017-16343-z

Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. / Sá, Ana Caroline C.; Webb, Amy; Gong, Yan; McDonough, Caitrin W.; Datta, Somnath; Langaee, Taimour Y.; Turner, Stephen T; Beitelshees, Amber L.; Chapman, Arlene B.; Boerwinkle, Eric; Gums, John G.; Scherer, Steven E.; Cooper-Dehoff, Rhonda M.; Sadee, Wolfgang; Johnson, Julie A.

In: Scientific Reports, Vol. 7, No. 1, 16068, 01.12.2017.

Research output: Contribution to journalArticle

Sá, ACC, Webb, A, Gong, Y, McDonough, CW, Datta, S, Langaee, TY, Turner, ST, Beitelshees, AL, Chapman, AB, Boerwinkle, E, Gums, JG, Scherer, SE, Cooper-Dehoff, RM, Sadee, W & Johnson, JA 2017, 'Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics', Scientific Reports, vol. 7, no. 1, 16068. https://doi.org/10.1038/s41598-017-16343-z
Sá, Ana Caroline C. ; Webb, Amy ; Gong, Yan ; McDonough, Caitrin W. ; Datta, Somnath ; Langaee, Taimour Y. ; Turner, Stephen T ; Beitelshees, Amber L. ; Chapman, Arlene B. ; Boerwinkle, Eric ; Gums, John G. ; Scherer, Steven E. ; Cooper-Dehoff, Rhonda M. ; Sadee, Wolfgang ; Johnson, Julie A. / Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{5df5618b333f4cdaa84e74f58a10266b,
title = "Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics",
abstract = "Thiazide diuretics (TD) are commonly prescribed anti-hypertensives worldwide. However, <40{\%} of patients treated with thiazide monotherapy achieve BP control. This study uses whole transcriptome sequencing to identify novel molecular markers associated with BP response to TD. We assessed global RNA expression levels in whole blood samples from 150 participants, representing patients in the upper and lower quartile of BP response to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) (50 whites) and from PEAR-2 (50 whites and 50 blacks). In each study cohort, we performed poly-A RNA-sequencing in baseline samples from 25 responders and 25 non-responders to hydrochlorothiazide (HCTZ) or chlorthalidone. At FDR adjusted p-value < 0.05, 29 genes were differentially expressed in relation to HCTZ or chlorthalidone BP response in whites. For each differentially expressed gene, replication was attempted in the alternate white group and PEAR-2 blacks. CEBPD (meta-analysis p = 1.8 × 10-11) and TSC22D3 (p = 1.9 × 10-9) were differentially expressed in all 3 cohorts, and explain, in aggregate, 21.9{\%} of response variability to TD. This is the first report of the use of transcriptome-wide sequencing data to identify molecular markers of antihypertensive drug response. These findings support CEBPD and TSC22D3 as potential biomarkers of BP response to TD.",
author = "S{\'a}, {Ana Caroline C.} and Amy Webb and Yan Gong and McDonough, {Caitrin W.} and Somnath Datta and Langaee, {Taimour Y.} and Turner, {Stephen T} and Beitelshees, {Amber L.} and Chapman, {Arlene B.} and Eric Boerwinkle and Gums, {John G.} and Scherer, {Steven E.} and Cooper-Dehoff, {Rhonda M.} and Wolfgang Sadee and Johnson, {Julie A.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-16343-z",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics

AU - Sá, Ana Caroline C.

AU - Webb, Amy

AU - Gong, Yan

AU - McDonough, Caitrin W.

AU - Datta, Somnath

AU - Langaee, Taimour Y.

AU - Turner, Stephen T

AU - Beitelshees, Amber L.

AU - Chapman, Arlene B.

AU - Boerwinkle, Eric

AU - Gums, John G.

AU - Scherer, Steven E.

AU - Cooper-Dehoff, Rhonda M.

AU - Sadee, Wolfgang

AU - Johnson, Julie A.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Thiazide diuretics (TD) are commonly prescribed anti-hypertensives worldwide. However, <40% of patients treated with thiazide monotherapy achieve BP control. This study uses whole transcriptome sequencing to identify novel molecular markers associated with BP response to TD. We assessed global RNA expression levels in whole blood samples from 150 participants, representing patients in the upper and lower quartile of BP response to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) (50 whites) and from PEAR-2 (50 whites and 50 blacks). In each study cohort, we performed poly-A RNA-sequencing in baseline samples from 25 responders and 25 non-responders to hydrochlorothiazide (HCTZ) or chlorthalidone. At FDR adjusted p-value < 0.05, 29 genes were differentially expressed in relation to HCTZ or chlorthalidone BP response in whites. For each differentially expressed gene, replication was attempted in the alternate white group and PEAR-2 blacks. CEBPD (meta-analysis p = 1.8 × 10-11) and TSC22D3 (p = 1.9 × 10-9) were differentially expressed in all 3 cohorts, and explain, in aggregate, 21.9% of response variability to TD. This is the first report of the use of transcriptome-wide sequencing data to identify molecular markers of antihypertensive drug response. These findings support CEBPD and TSC22D3 as potential biomarkers of BP response to TD.

AB - Thiazide diuretics (TD) are commonly prescribed anti-hypertensives worldwide. However, <40% of patients treated with thiazide monotherapy achieve BP control. This study uses whole transcriptome sequencing to identify novel molecular markers associated with BP response to TD. We assessed global RNA expression levels in whole blood samples from 150 participants, representing patients in the upper and lower quartile of BP response to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) (50 whites) and from PEAR-2 (50 whites and 50 blacks). In each study cohort, we performed poly-A RNA-sequencing in baseline samples from 25 responders and 25 non-responders to hydrochlorothiazide (HCTZ) or chlorthalidone. At FDR adjusted p-value < 0.05, 29 genes were differentially expressed in relation to HCTZ or chlorthalidone BP response in whites. For each differentially expressed gene, replication was attempted in the alternate white group and PEAR-2 blacks. CEBPD (meta-analysis p = 1.8 × 10-11) and TSC22D3 (p = 1.9 × 10-9) were differentially expressed in all 3 cohorts, and explain, in aggregate, 21.9% of response variability to TD. This is the first report of the use of transcriptome-wide sequencing data to identify molecular markers of antihypertensive drug response. These findings support CEBPD and TSC22D3 as potential biomarkers of BP response to TD.

UR - http://www.scopus.com/inward/record.url?scp=85034809954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034809954&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-16343-z

DO - 10.1038/s41598-017-16343-z

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16068

ER -